Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1

Y. Takada, L. Gresh, A. Bozec, E. Ikeda, K. Kamiya, M. Watanabe, K. Kobayashi, K. Asano, Y. Toyama, E. F. Wagner, K. Matsuo

研究成果: Article査読

23 被引用数 (Scopus)


The role of the AP-1 transcription factor Fra-1 (encoded by Fosl1) in inflammatory responses associated with lung disease is largely unknown. Here, we show that Fra-1 overexpression in mice reduced proinflammatory cytokine production in response to injection of lipopolysaccharide (LPS), a Toll-like receptor (TLR)-ligand. Unexpectedly, Fra-1 transgenic mice died rapidly following LPS treatment, showing severe interstitial lung disease and displaying massive accumulation of macrophages and overproduction of several chemokines, including macrophage chemoattractant protein-1 (MCP-1, encoded by Ccl2). To assess the clinical relevance of Fra-1 in lung pathology, mice were treated with the anticancer drug gefitinib (Iressa), which can lead to interstitial lung disease in patients. Gefitinib-treated mice showed increased Fosl1 and Ccl2 expression and developed interstitial lung disease in response to LPS, endogenous TLR ligands and chemotherapy. Moreover, deletion of Fra-1 or blocking MCP-1 receptor signaling in mice attenuated gefitinib-enhanced lethality in response to LPS. Importantly, human alveolar macrophages showed enhanced LPS-induced FOSL1 and CCL2 expression after gefitinib treatment. These results indicate that Fra-1 is an important mediator of interstitial lung disease following gefitinib treatment.

出版ステータスPublished - 2011 9月 8

ASJC Scopus subject areas

  • 分子生物学
  • 遺伝学
  • 癌研究


「Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。